Kestra Investment Management LLC Acquires 9,551 Shares of Gilead Sciences, Inc. $GILD

Kestra Investment Management LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 683.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,949 shares of the biopharmaceutical company’s stock after acquiring an additional 9,551 shares during the quarter. Kestra Investment Management LLC’s holdings in Gilead Sciences were worth $1,214,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Activest Wealth Management raised its holdings in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. GoalVest Advisory LLC raised its stake in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences in the 2nd quarter worth about $27,000. Putney Financial Group LLC boosted its stake in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the period. Finally, Howard Hughes Medical Institute bought a new position in Gilead Sciences during the 2nd quarter valued at about $30,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Down 2.3%

NASDAQ GILD opened at $120.40 on Monday. Gilead Sciences, Inc. has a one year low of $88.57 and a one year high of $128.70. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The company has a market capitalization of $149.38 billion, a price-to-earnings ratio of 18.67, a price-to-earnings-growth ratio of 0.67 and a beta of 0.32. The company’s 50-day simple moving average is $121.89 and its two-hundred day simple moving average is $115.81.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Royal Bank Of Canada boosted their target price on Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a research report on Friday, October 31st. Citigroup boosted their price objective on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. BMO Capital Markets set a $135.00 target price on shares of Gilead Sciences in a research note on Tuesday, November 25th. Finally, Daiwa Capital Markets upped their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $131.13.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $126.54, for a total transaction of $1,265,400.00. Following the completion of the transaction, the chief executive officer owned 571,203 shares in the company, valued at $72,280,027.62. The trade was a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the sale, the insider owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. This represents a 20.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 130,257 shares of company stock worth $15,991,492. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.